What is Sustanon 400?
Sustanon 400 is the higher-concentration variant of the test ester mix: the same principle as Sustanon 250, but 400mg testosterone esters per ml. The only advantage is the smaller injection volume, the effect is the same as any testosterone preparation.
This is a ready-to-use anabolic steroid, not a peptide.
Comparison
One ester or four
The same compound at the same receptor with esters of different length, as stated in the TPD lexicon. Tap a card to open its entry.
Simplified: the ester only sets how fast testosterone is released from the depot. At the receptor it is always the same testosterone. 211
How it works
As with Sustanon 250, the actual compound is testosterone, released from different esters. It binds the androgen receptor and drives muscle growth, strength and male hormone effects. The higher concentration only changes the volume per injection, not the pharmacology.
Where it acts
Where the classic blend acted in studies
Tap a point or a card. Grey = observed in studies, all via the androgen receptor.
- Pituitary
LH fell in young men, back to baseline after stopping8
Observed in trials - Testes
Leydig cell marker INSL3 fell, recovered after stopping8
Observed in trials - Skeletal muscle
More fat-free mass, muscle thickness and strength than with training alone5
Observed in trials - Fat tissue
Total fat mass fell within 6 weeks5
Observed in trials - Bone
Spine bone density +5 percent, bone breakdown slowed6
Observed in trials - Blood
Red blood cell values shifted, more young red blood cells3
Observed in trials
Targets in the ChEMBL database15
Compound CHEMBL386630: one recorded mechanism, Agonist, direct binding (testosterone).
- Gene
- AR
- UniProt
- P10275
- ChEMBL
- CHEMBL1871
- Action
- Agonist, direct binding (testosterone)
Use
Dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
As with Sustanon 250: testosterone esters are established as hormone replacement, the anabolic pharmacology is broadly described (Yarrow, 2010). The high concentration is only a formulation matter, not its own evidence base. High doses are not covered by controlled studies.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Protein gain in muscle per day5
Older men (65 to 75 years), 6 weeks of strength training, injection every 2 weeks, 9 participants each
Muscle protein synthesis ran at 2.13 percent per day with the blend and 1.34 percent with placebo. Breakdown rose too, but on balance clearly more protein stayed in the muscle.
Lumbar spine bone density67
Change in percent on the classic four-ester blend
Abstract values 5 and 5.0 percent. In the cortisone study bone density did not change without testosterone; in the control phase fat mass rose and lean mass fell, both reversed with testosterone.
Flagged profiles after two injections3
Share of the 9 men on the blend, randomised against placebo
Steroid profile flagged in 9 of 9, blood profile in 6 of 9 (shown as a share). The share of young red blood cells (reticulocytes) showed the use best, mainly 3 to 10 days later.
Research status
Where the research stands
There is no study on Sustanon 400 itself. Shown are registered trials with the classic four-ester blend (Sustanon 250), mostly as testosterone replacement in hormone deficiency. As of 25 Oct 2026. 14
- Preclinical Animal model (rats): testes and sperm production
- Phase 1 1 trial on components, 0 completed
- Phase 2 no registered trial
- Phase 3 1 trial on components, 1 completed
- Approval no study of this strength
Show all 13 trials on a timelineHide timeline
CDGP · NCT01797718 · 35 participants, started Oct 2013, primary endpoint reached Mar 2017. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT00355537 · 19 participants, started Feb 2006, primary endpoint reached Dec 2009.
Registry entry ↗ · Results not yet in PubMed
NCT01601327 · 119 participants, started Jan 2008, primary endpoint reached Mar 2012. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT01107067 · 32 participants, started Jun 2008, primary endpoint reached Dec 2009.
Registry entry ↗ · Results not yet in PubMed
NCT01533129 · 106 participants, started Aug 2008, primary endpoint reached Apr 2011. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT02171390 · 130 participants, started Aug 2008, primary endpoint reached Jun 2012. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT01454011 · 140 participants, started Sept 2008, primary endpoint reached Feb 2011. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT02111473 · 49 participants, started May 2009, primary endpoint reached May 2012.
Registry entry ↗ · Results not yet in PubMed
NCT01160341 · 312 participants, started Aug 2009, primary endpoint reached Jan 2010.
Registry entry ↗ · Results not yet in PubMed
NCT02111434 · 150 participants, started Jul 2013, primary endpoint reached Apr 2014.
Registry entry ↗ · Results not yet in PubMed
NCT01758094 · 25 participants, started Jan 2008, primary endpoint reached Aug 2012.
Registry entry ↗ · Results not yet in PubMed
NCT02571205 · 15 participants, started Nov 2015, primary endpoint reached Feb 2019.
Registry entry ↗ · Results not yet in PubMed
ASCEND001 · NCT07568574 · 60 participants (planned), started Mar 2026, primary endpoint planned May 2028. Tests several agents.
Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 25 Oct 2026. Phase 1: 1 trial on safety and pharmacokinetics, not shown as bars.
Side effects
- Like Sustanon 250, but easier to overdose due to the high concentration.
- Estrogen-related effects, axis suppression, lipid shift.
- Higher doses raise the cardiovascular load.
Practice
-
Dose precisely, the high concentration does not forgive crude syringe errors.
-
Watch bloodwork, plan a post-cycle.
-
Banned in official competition (WADA S1).
Storage
Store at room temperature, cool and protected from light, out of reach of children. Keep the original bottle closed and mind the expiry date.